Austin, TX-based Mirna Therapeutics became more connected and invigorated with the appointment of biopharmaceutical titan Clay B. Siegall to their Board of Directors.
Siegall is well known in the industry for innovative work regarding cancer research and treatment. Mirna will certainly benefit from his expertise in the field while developing their extensive line of cancer treatment products.
The name Mirna is derived from the term microRNA which is used to describe genetic control switches in the body that could one day lead to a cure for cancer. MicroRNA is one of the most progressive areas of cancer treatment with the potential to eliminate the disease that has plagued mankind for millennia.
With Clay Siegall’s leadership and connections, Mirna is positioned to be on the cutting edge of cancer therapy. They already have a number of products in the pipeline with more to come in the future.
Siegall is best known for his leadership role at Seattle Genetics, which he co-founded back in 1998. The Seattle-based company has already created a diverse line of antibody-based treatments previously unavailable to cancer patients. Siegall also serves on the Board of Directors for Alder BioPharmaceuticals, creating another important link between biotech companies on the front lines of cancer treatment.
Siegall’s previous accomplishments include a Ph.D. in genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He also contributed to the National Cancer Institute and the Squibb Pharmaceutical Research Institute, along with a handful of other biotech companies. On top of his epic resume, he has also been published over 70 times and holds 15 patents.
There’s no doubt that Clay Siegall’s extensive experience and insight will help steer Mirna in the right direction moving forward. His ability to secure venture capital will also provide the company with the much-needed funding to continue their research efforts.
Clay B Siegall became the president and CEO of Seattle Genetics, in which he found in 1988. He worked in several fields in the past such as Bristol Myers-Squibb Pharmaceutical research institute, National Cancer institute, National institutes of health and Alder BioPharmecuticals and Mirna Therapeutics.
Purpose/Goal of Company
It’s hard to imagine the physical and mental distress faced by cancer patients as they undergo chemotherapy. This occurs because chemotherapy targets normal, non-cancerous cells although they’re harmless. What if there’s a way that chemotherapy can destroy cancerous cells while leaving the regular ones unaffected? Seattle Genetics can solve this problem.
The company creates antibodies that can supplement chemo while only eliminating cancerous cells. These antibodies promotes anti-tumor activities and bypassess ordinary cells from being destroyed. As a result, hair-loss, tiredness from being anemic, bruises and sores that cancer patients face are reduced.
Several products are currently under development for effectiveness such as the SGN and ASN line of antibodies. ADCETRIS is currently used for relasped Hodgkin Lymphoma patients and it is currently available in the U.S an Canada.
The company hopes to commercialize and distribute their products to many hospitals and facilities. Their mission is a large effort to improve the quality of cancer treatment.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Mechanism of ADC Technology
The products created by Seattle Genetics involve an antibody-drug conjugate that is designed for a tumor associated antigen. The links that bind “Cytoxic” agents to the anti-body are released towards the antigen, destroying it. The anti-body gets inside of the cell by binding to an outside receptor. Once it’s inside of the cell, apoptosis occurs when the cytoxic agents are released. This also causes destruction of the anti-body.
Seattle genetics is pioneering a new stage of cancer treatment where patients are less damaged and have a better chance of survival. There’s little to know what potential these products have.